Menu
Have you had a chance to explore our tools?
The US recently signed into law its historic Inflation Reduction Act, paving the way for public payer negotiation …
Strategy
Delivered a suite of services, including a value story slide deck consisting of impactful messages and supporting graphics, cost-effectiveness and budget impact models, systematic literature review to fill evidence gaps for value story and models, as well as a health technology assessment (HTA) dossier and objection handler
Analytics
Given the required timeframe, concluded that generating new data/prospective study was not feasible. Hence, shortlisted potential databases/registries already licensed that would have the required patient exposure and outcomes of interest. Analysed company’s existing UK THIN and US Truven MarketScan databases using R
Modelling
Reviewed disease area literature to understand quality of life and costs, benefit of treatment, as well as market share and revenue forecasts. Developed an integrated value assessment model (VAM) that allowed the team to test changes in the target product profile and pricing methodology on the overall value
Visualization
Reviewed current study protocols, endpoints, value messages and overall value proposition, as well as existing study trackers. Proposed our unique VNV that stored every relationship between a study, its endpoints and intended value messages as pathways along with additional supporting information in the data matrix. Click for an interactive demo:
Training
Reviewed company’s existing RWE studies and interviewed key team members to understand RWE capabilities, as well as product priorities and challenges. Developed a training workshop to empower the team to address product challenges using RWE consisting of:
Strategy
Delivered a suite of services, including a value story slide deck consisting of impactful messages and supporting graphics, cost-effectiveness and budget impact models, systematic literature review to fill evidence gaps for value story and models, as well as a health technology assessment (HTA) dossier and objection handler
Analytics
Given the required timeframe, concluded that generating new data/prospective study was not feasible. Hence, shortlisted potential databases/registries already licensed that would have the required patient exposure and outcomes of interest. Analysed company’s existing UK THIN and US Truven MarketScan databases using R
Modelling
Reviewed disease area literature to understand quality of life and costs, benefit of treatment, as well as market share and revenue forecasts. Developed an integrated value assessment model (VAM) that allowed the team to test changes in the target product profile and pricing methodology on the overall value
Visualization
Reviewed current study protocols, endpoints, value messages and overall value proposition, as well as existing study trackers. Proposed our unique VNV that stored every relationship between a study, its endpoints and intended value messages as pathways along with additional supporting information in the data matrix. Click for an interactive demo:
Training
Reviewed company’s existing RWE studies and interviewed key team members to understand RWE capabilities, as well as product priorities and challenges. Developed a training workshop to empower the team to address product challenges using RWE consisting of:
